Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but there could still be a solid upside left in the stock if short-term price ...

Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Septerna, Inc. (SEPN – Research Report) on May 15 and set a price target of $25.00. The company’s shares c ...

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Blood and urine tests might be able to reveal how much of your diet is made up of industrially produced foods, a new study ...

We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.

Septerna has been working on small-molecule drugs that can target one or multiple of those targets at the same time, according to a recent company presentation, which indicates it has identified a ...

About a fourth of younger men surveyed in the United States feel lonely, which is significantly higher than the national ...

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...